| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
|
Kneebone, Andrew
|
|
|
21 |
10 |
p. 1331-1340
|
artikel
|
| 2 |
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
|
Sargos, Paul
|
|
|
21 |
10 |
p. 1341-1352
|
artikel
|
| 3 |
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
|
Marabelle, Aurélien
|
|
|
21 |
10 |
p. 1353-1365
|
artikel
|
| 4 |
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
|
Telli, Melinda L
|
|
|
21 |
10 |
p. 1254-1255
|
artikel
|
| 5 |
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
|
Kumar, Shaji K
|
|
|
21 |
10 |
p. 1317-1330
|
artikel
|
| 6 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|
Turner, Nicholas C
|
|
|
21 |
10 |
p. 1296-1308
|
artikel
|
| 7 |
Correction to Lancet Oncol 2020; 21: 1309–16
|
|
|
|
21 |
10 |
p. e462
|
artikel
|
| 8 |
Correction to Lancet Oncol 2019; 20: 193–201
|
|
|
|
21 |
10 |
p. e462
|
artikel
|
| 9 |
Correction to Lancet Oncol 2020; 21: 796–807
|
|
|
|
21 |
10 |
p. e462
|
artikel
|
| 10 |
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
|
Lee, Lennard Y W
|
|
|
21 |
10 |
p. 1309-1316
|
artikel
|
| 11 |
Demystifying the estimand framework: a case study using patient-reported outcomes in oncology
|
Fiero, Mallorie H
|
|
|
21 |
10 |
p. e488-e494
|
artikel
|
| 12 |
Ethical concerns regarding private equity in Right to Try in the USA
|
Lee, Susannah W
|
|
|
21 |
10 |
p. 1260-1262
|
artikel
|
| 13 |
Gastric cancer risk: between genetics and lifestyle
|
Rugge, Massimo
|
|
|
21 |
10 |
p. 1258-1260
|
artikel
|
| 14 |
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study
|
Jin, Guangfu
|
|
|
21 |
10 |
p. 1378-1386
|
artikel
|
| 15 |
Less Survivable Cancers Taskforce calls for faster diagnosis
|
Burki, Talha Khan
|
|
|
21 |
10 |
p. 1265-1266
|
artikel
|
| 16 |
Oncology training in Latin America: are we ready for 2040?
|
Duma, Narjust
|
|
|
21 |
10 |
p. 1267-1268
|
artikel
|
| 17 |
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
|
Bonvalot, Sylvie
|
|
|
21 |
10 |
p. 1366-1377
|
artikel
|
| 18 |
SSO 2020 virtual meeting
|
Lai, Cheryl
|
|
|
21 |
10 |
p. 1263
|
artikel
|
| 19 |
Stewart–Treves syndrome: a rapidly fatal complication of breast cancer treatment
|
Hsu, Andrew
|
|
|
21 |
10 |
p. e495
|
artikel
|
| 20 |
The STRASS trial: an important step in the right direction
|
Cardona, Kenneth
|
|
|
21 |
10 |
p. 1257-1258
|
artikel
|
| 21 |
Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia
|
Wong, Jeffrey Y C
|
|
|
21 |
10 |
p. e477-e487
|
artikel
|
| 22 |
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
|
Emens, Leisha A
|
|
|
21 |
10 |
p. 1283-1295
|
artikel
|
| 23 |
Treatment after progression in the era of immunotherapy
|
Billan, Salem
|
|
|
21 |
10 |
p. e463-e476
|
artikel
|
| 24 |
Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)
|
Bersanelli, Melissa
|
|
|
21 |
10 |
p. 1255-1257
|
artikel
|
| 25 |
2020 US election and implications for cancer care
|
Nierengarten, Mary Beth
|
|
|
21 |
10 |
p. 1264-1265
|
artikel
|
| 26 |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Diéras, Véronique
|
|
|
21 |
10 |
p. 1269-1282
|
artikel
|
| 27 |
Will cancer care be a winner in the US election?
|
The Lancet Oncology,
|
|
|
21 |
10 |
p. 1253
|
artikel
|
Tijdschrift beschrijving